The evolution of Parkinson's disease is very slow and still inexorable today. It consists of various well-defined steps that allow all health professionals: doctors, home health providers, nurses, and physiotherapists, etc. to adapt their care at each stage to improve the quality of life.

Evolution of Parkinson's disease: the different stages of evolution

How is Parkinson's disease evolving? Its evolution is slow and progressive and consists of several steps well identified today. Nevertheless, the pace of this evolution remains unpredictable and very variable from one person to another. It depends on different individual factors, among which:

        The response to Dopa therapy (dopaminergic treatment with levodopa)

        The age of onset of the disease

        The main symptom

        The localization of disorders in the lower limbs

        The emotional state (stress, motivation, fatigue, etc.).

Stage 1: The first signs of Parkinson's disease

It generally takes between 5 and 10 years between the first signs of Parkinson's disease and its official diagnosis, even though it is already well established and has evolved silently.

Three symptoms of Parkinson's disease must, therefore, raise questions about its presence and encourage consultation with neurology surgery hospitals in Delhi, where there is symptoms like: resting tremors, slow movements (bradykinesia) and stiffness of a patient. At this point, Parkinson's disease does not affect your professional and personal lives too much.

Stage 2: The "honeymoon" of Parkinson's disease

The initiation of dopaminergic treatment with levodopa when the symptoms of Parkinson's disease are both more present and disabling allow a clear improvement in the situation. This parenthesis in the disease lasts from 3 to 8 years. The effectiveness of the treatment is optimal, and its side effects relatively limited, life can be conducted almost normally. This is the "honeymoon" of Parkinson's.

Stage 3: Motor complications induced by dopa-therapy

Oral treatments at fixed hours can effectively compensate for the dopamine deficiency characteristic of Parkinson's disease in the early years. However, this benefit gradually fades and the therapeutic window - the dose at which efficacy and tolerance to drugs is the best - is reduced.

After several years of dopa therapy, complications arise. It is mainly motor fluctuations (characterized by a recovery of symptoms with alternating phases "on" and "off" phases that affect all patients after 10 years of treatment) and dyskinesias (90% of patients after 10 years treatment). The appearances of archeology of awakening and end of dose are the first signs heralding this new phase of the disease. The symptoms then become more intense and unpredictable.

These complications invite neurology hospitals in Indiato review the therapeutic strategy, first by adjusting the treatment (doses, schedules of catches, etc.), or even considering switching to dopaminergic continuous pump stimulation. In practice, the continuous infusion of apomorphine pump is put in place when several injections of apomorphine are necessary. The benefits described in the literature are:

        Reduction of 40 to 80% of the engine blocking time "off."

        30 to 64% reduction in dyskinesia

        48 to 55% reduction in levodopa doses